ArticleDiabetologia2006
Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.
Article in Diabetologia, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.Journal of the American Society of Nephrology : JASN · 2015Trial
- The relationship of retinal vessel diameter to changes in diabetic nephropathy structural variables in patients with type 1 diabetes.Diabetologia · 2010Trial
- High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?International journal of molecular sciences · 2025Review
- Association between hyperuricemia and diabetic nephropathy: insights from the national health and nutrition examination survey 2007-2016 and mendelian randomization analysis.International urology and nephrology · 2024Observational
- Secretory leukocyte protease inhibitor as a novel predictive biomarker in patients with diabetic kidney disease.Frontiers in endocrinology · 2024Article
- Review
- The Prevalence and Risk Factors of Diabetic Retinopathy: Screening and Prophylaxis Project in 6 Provinces of China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Clinical value of INSL3 in the diagnosis and development of diabetic nephropathy.Journal of clinical laboratory analysis · 2021Article
- Evidence of Early Diabetic Nephropathy in Pediatric Type 1 Diabetes.Frontiers in endocrinology · 2021Article
- Are blood lipids associated with microvascular complications among type 2 diabetes mellitus patients? A cross-sectional study in Shanghai, China.Lipids in health and disease · 2019Article
- The Effect of Vitamin D on Cellular Pathways of Diabetic Nephropathy.Reports of biochemistry & molecular biology · 2019Article
- Elevated urinary N-acetyl-β-D-glucosaminidase is associated with high glycoalbumin-to-hemoglobin A1c ratio in type 1 diabetes patients with early diabetic kidney disease.Scientific reports · 2018Article
- Proteome Profiling of Diabetic Mellitus Patient Urine for Discovery of Biomarkers by Comprehensive MS-Based Proteomics.Proteomes · 2018Article
- Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes.Diabetologia · 2017Article
- HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study.BMC nephrology · 2016Article
- Article
- Diabetic kidney disease: a report from an ADA Consensus Conference.Diabetes care · 2014Article
- The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Diabetes & vascular disease research · 2014Review
- Comprehensive approach to diabetic nephropathy.Kidney research and clinical practice · 2014Review
- Why do some patients with type 1 diabetes live so long?World journal of diabetes · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy is a major problem for patients and health care systems. The costs of treatment remain high. To confront the ongoing challenge, we need to identify individuals at high risk for initiation and progression of this devastating complication. Risk factors include genetic markers; constitutional factors such as low birthweight; haemodynamic factors, including activation of the RAS system and hypertension; metabolic factors such as glycaemia; and additional factors such as urinary AER and smoking. Modifiable risk factors should be treated aggressively. Potential new markers of risk include indices of increased inflammation, changes in coagulation, endothelial dysfunction, growth factors and cytokines. Application of such markers may in time improve risk assessment and allow new treatment targets to be identified. Interventions that aim to achieve strict glycaemic control and blockade of the renin-angiotensin system have been shown to be effective in clinical trials and are feasible in clinical practice. The 'natural history' of diabetic nephropathy can be transformed if these strategies of intensive screening and care are applied, leading both to a lower incidence of diabetic nephropathy and to an improved outcome, with survival exceeding 20 years from onset of overt proteinuria.
Indexed as
Identifiers
16341685What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.